Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Raji Sridhara"'
Publikováno v:
Clinical Cancer Research. 10:8147-8151
Purpose: Docetaxel, a taxane previously approved for the treatment of breast cancer and non–small cell lung cancer, was approved by the United States Food and Drug Administration on May 19, 2004 for use in combination with prednisone for the treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed3c393fc725176fe0f3a0ed9f701962
https://doi.org/10.1158/1078-0432.ccr-04-1402
https://doi.org/10.1158/1078-0432.ccr-04-1402
Autor:
Douglas D. Ross, Patricia J. Wooten, Charles A. Schiffer, José V. Ordóñez, Raji Sridhara, Edward J. Lee
Publikováno v:
Blood. 82:1288-1299
This work was designed to discern the frequency of expression of classical multidrug resistance (MDR) in acute myeloid leukemia (AML) at the time of diagnosis, using Western blotting for P-glycoprotein (Pgp) and functional assays for an MDR phenotype
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de5a385856294c3b2123b18fa779f5e6
https://doi.org/10.1182/blood.v82.4.1288.1288
https://doi.org/10.1182/blood.v82.4.1288.1288
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 10(24)
Docetaxel, a taxane previously approved for the treatment of breast cancer and non-small cell lung cancer, was approved by the United States Food and Drug Administration on May 19, 2004 for use in combination with prednisone for the treatment of meta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ee55e9bcb33a7ed924ea8b66e8a75a72
https://pubmed.ncbi.nlm.nih.gov/15623588
https://pubmed.ncbi.nlm.nih.gov/15623588
Autor:
Melanie M. Bell, Joseph Aisner, D. Hiponia, Teresa J. Melink, Chandra P. Belani, Jeffrey S. Abrams, Raji Sridhara, William H. Adler, Julie L. Eiseman
Publikováno v:
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy. 14(1)
The objective of this phase IB trial was to determine if cyclophosphamide (CY) could enhance the immune effects of interleukin-2 (IL-2), and if it could, was there an optimal immunomodulatory dosage. IL-2 alone at 30 million IU/m2 thrice weekly for 6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af749abfbdc54760df77ea84a3afe32e
https://pubmed.ncbi.nlm.nih.gov/8399071
https://pubmed.ncbi.nlm.nih.gov/8399071